Physician profile
Vivek Narain
NPI 1598743031
$2,917.59
in general payments reported to CMS, 2019-2025
34 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $236 · 2021: $649 · 2022: $611 · 2023: $430 · 2024: $335 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $591.53 | 2019-2023 | |
| Coloplast Corp | $442.57 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $263.06 | 2023-2025 | Gemtesa |
| Abbvie INC. | $179.83 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $164.01 | 2022 | |
| Neotract INC. | $137.03 | 2019 | |
| Pfizer INC. | $134.63 | 2022-2025 | |
| Urogen Pharma, INC. | $115.74 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $96.40 | 2021-2024 | Lynparza, Keytruda |
| Boston Scientific Corporation | $89.25 | 2019-2023 | Tria Firm |
| Axonics, INC. | $67.61 | 2022-2024 | Axonics |
| Janssen Biotech, INC. | $62.67 | 2022-2025 | Erleada |
| Olympus America INC. | $50.93 | 2019-2025 | Soltive, Hd Camera Head |
| Allergan, INC. | $49.52 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $48.57 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $44.18 | 2020-2025 | Provenge |
| Bioprotect Medical, INC. | $38.82 | 2025 | Bioprotect Balloon Implant System |
| Urovant Sciences INC | $38.38 | 2021-2022 | |
| Procept Biorobotics Corporation | $33.52 | 2025 | |
| Ferring Pharmaceuticals INC. | $32.01 | 2019 | |
| Blue Earth Diagnostics | $31.18 | 2024 | |
| Becton, Dickinson and Company | $30.65 | 2023 | Bard Urinary Drainage Bag |
| Antares Pharma, INC. | $29.63 | 2024 | Xyosted |
| Amgen INC. | $22.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.23 | 2022 | |
| Verity Pharmaceuticals INC. | $20.22 | 2025 | Trelstar |
| Ambu INC. | $17.56 | 2020 | |
| Palette Life Sciences, INC. | $14.85 | 2023 | |
| Clarus Therapeutics INC. | $14.85 | 2021 | |
| Photocure INC | $14.82 | 2025 | Cysview |
| Rgh Enterprises LLC | $12.05 | 2019 | |
| Laborie Medical Technologies Corp. | $7.89 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$256,451.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.